Clinical Trial

A Phase I Trial of QLS2313 Injection in Relapsed/Refractory Hematological Malignancies

Name: A Phase I Trial of QLS2313 Injection in Relapsed/Refractory Hematological Malignancies — clinical trial record (NCT07294300)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

This study is an open-label, dose-escalation and efficacy-expansion Phase I clinical trial to evaluate the safety, tolerability, PK profile, immunogenicity, and preliminary antitumor activity of QLS2313 as a monotherapy in patients with relapsed/refractory hematological malignancies.

Trial Details

NCT Number	NCT07294300
Lead Sponsor	Qilu Pharmaceutical Co., Ltd.
Conditions	Relapsed/Refractory Hematological Malignancies
Enrollment	124 participants
Start Date	2026-01
Primary Completion	2028-02 (estimated)
Study Completion	2028-02 (estimated)
Updated on ClinicalTrials.gov	2025-12-19